Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish Sells 19,256 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO) CEO Bhatnagar Anish sold 19,256 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $41.54, for a total transaction of $799,894.24. Following the completion of the sale, the chief executive officer now directly owns 133,534 shares of the company’s stock, valued at $5,547,002.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Soleno Therapeutics Stock Up 5.8 %

Shares of SLNO stock opened at $42.03 on Thursday. Soleno Therapeutics, Inc. has a one year low of $3.69 and a one year high of $53.82. The stock has a fifty day moving average price of $43.34 and a 200 day moving average price of $43.31.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.29). On average, research analysts forecast that Soleno Therapeutics, Inc. will post -2.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Cannon Global Investment Management LLC acquired a new position in shares of Soleno Therapeutics in the 1st quarter worth approximately $505,000. Aspiriant LLC bought a new stake in Soleno Therapeutics in the fourth quarter valued at $488,000. Sei Investments Co. grew its position in Soleno Therapeutics by 22.0% in the first quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock valued at $538,000 after acquiring an additional 2,264 shares during the period. California State Teachers Retirement System raised its stake in Soleno Therapeutics by 33.8% during the first quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock worth $590,000 after acquiring an additional 3,481 shares in the last quarter. Finally, Swiss National Bank bought a new position in shares of Soleno Therapeutics during the fourth quarter valued at $918,000. 97.42% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SLNO has been the topic of several recent research reports. Robert W. Baird started coverage on Soleno Therapeutics in a report on Friday, May 10th. They set an “outperform” rating and a $72.00 target price on the stock. Baird R W upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research note on Friday, May 10th. Finally, Oppenheimer decreased their price target on shares of Soleno Therapeutics from $65.00 to $59.00 and set an “outperform” rating on the stock in a research report on Monday, May 13th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $60.33.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.